As Eli Lilly ends the year with Zepbound in good supply, TD Cowen analyst Steve Scala asked CEO David Ricks if the company ...
Eli Lilly reported fourth quarter and full year earnings for 2024 Thursday, with results largely beating Wall Street ...
Eli Lilly’s profit doubled in the fourth ... with a mostly better-than-expected 2025 forecast. Sales of Lilly’s top-selling product, the diabetes treatment Mounjaro, jumped 60% to $3.53 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback